About
Peptides, Antibodies
Areas of Focus
Categories
Non-PharmaceuticalAntibody
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
485
By Phase
PHASE2: 1PHASE1/PHASE2: 2
By Status
COMPLETED: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
Today
Hover over trial bars to see details
Recent Trials
NCT05639166Lead Sponsor
Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19
PHASE2Completed
200 participants
Started: Feb 18, 2023 · Completed: May 16, 2023
NCT05303376Lead Sponsor
Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness
PHASE1/PHASE2Completed
123 participants
Started: Feb 22, 2022 · Completed: Jun 27, 2023
NCT05298813Lead Sponsor
Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness
PHASE1/PHASE2Completed
162 participants
Started: Sep 29, 2021 · Completed: Jan 4, 2023
Locations (1)
Headquarters
Sherbrooke, QC, Canada
Map
Loading map...